Indian pharma market grew 10.2% yoy in January 2026
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
Vanrafia, a potent endothelin A receptor antagonist, received accelerated approval in the US and China in 2025 for reducing proteinuria in adults with IgAN
The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
The NIRSE-GAL study, conducted in Galicia, Spain, is the first real-world, population-based investigation of a universal RSV immunization program spanning two consecutive seasons
The recommendation is based on new data from continuous safety monitoring of medicines in the EU
Duvakitug was well tolerated and safety was consistent with the induction study
mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe
MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control
Subscribe To Our Newsletter & Stay Updated